医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

GKIDA Launches Ultra-Light Portable Emergency Kit for Daily Living and Travel Safety

2023年10月25日 PM10:00
このエントリーをはてなブックマークに追加


 

SEOUL, South Korea

GKIDA, a disaster and safety supplies company, has launched an ultra-light portable emergency kit.

GKIDA’s ultra-light portable emergency kit weighs only 100 grams and includes first aid medicine, a raincoat, a lantern, a glow stick, and a whistle. The glowing-in-the-dark logo engraved on the case strap makes it easy to locate even in the dark. Users can avoid losing their kits by connecting them to the smart tracker app.

After years of shooting and volunteering in underdeveloped regions abroad, former documentary producer CEO Cho Sang-eun launched the brand GKIDA after realizing the need for survival and relief supplies that can protect people in emergencies. Following the release of Bandi, an emergency kit for novice travelers, CEO Cho also introduced GKIDA, an updated keychain design that can be easily attached to a bag.

People are always at risk from disasters and catastrophes. According to a report by the Korea Meteorological Administration, there were 68 earthquakes in Korea in 2020. With the prevalence of unpredictable disasters such as fires, collapses, and safety accidents, carrying a survival and relief kit can significantly improve your chances of survival.

Most existing survival and relief kits are bulky, heavy, and clumsy in design, making them inconvenient to carry. In contrast, the GKIDA’s portable survival and relief kit won the 2022 Good Design Award for both its remarkable design and survival functionality.

To learn more about the GKIDA Ultra-Light Portable Emergency Kit, please visit the website: https://gkida.com/

View source version on businesswire.com: https://www.businesswire.com/news/home/20231025991052/en/

CONTACT

EDL ENTERPRISE for GKIDA

Sujin Lee

lsj@edl.co.kr

同じカテゴリーの記事 

  • Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
  • Huonslab Announces Positive Results from In Vivo comparative PK study of Trastuzumab/HyDIFFUZETM compared with marketed rHuPH20 co-formulation with Trastuzumab
  • Rapid Medical™、TIGERTRIEVER™13を用いたDISTALS臨床試験の中間安全性解析で、中血管閉塞の安全性の懸念がないことを報告
  • Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration
  • JCR Pharmaceuticals’ Data Presentations at SSIEM Annual Symposium 2024 Highlight Investigational Treatments for Lysosomal Storage Disorders